WO2005005383A1 - Composé amino-alcool - Google Patents

Composé amino-alcool Download PDF

Info

Publication number
WO2005005383A1
WO2005005383A1 PCT/JP2004/010235 JP2004010235W WO2005005383A1 WO 2005005383 A1 WO2005005383 A1 WO 2005005383A1 JP 2004010235 W JP2004010235 W JP 2004010235W WO 2005005383 A1 WO2005005383 A1 WO 2005005383A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
group
amino
compound
butane
Prior art date
Application number
PCT/JP2004/010235
Other languages
English (en)
Japanese (ja)
Inventor
Takahide Nishi
Toshiyasu Takemoto
Shojiro Miyazaki
Takaichi Shimozato
Futoshi Nara
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of WO2005005383A1 publication Critical patent/WO2005005383A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms

Definitions

  • Such a compound (a) of the prior art has, as essential substituents, two oxymethyl groups (one CH 2 OR x 4 and —CH 2 R X 5 ) which substitute on the same carbon atom.
  • the compound is different from the above-mentioned compound (a) in that it has, as corresponding groups, one CH 2 ⁇ R 3 group and a lower alkyl group which are substituted by the same carbon atom.
  • X is a compound that is a sulfur atom or a pharmacologically acceptable salt thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé amino-alcool, ou un sel de celui-ci acceptable sur le plan pharmaceutique, qui possède une excellente activité immuno-inhibitrice. La structure du composé est représentée par la formule (I), dans laquelle R1 et R2 représentent chacun hydrogène ou alkyle inférieur ; R3 représente alkyle inférieur ; X représente soufre ou azote substitué par alkyle inférieur ; Y représente un groupe C(=O)-CH2- ; Z représente éthylène, etc. ; R4 représente aryle ou aryle substitué ; et R5 représente hydrogène, halogène, ou alkyle inférieur, à condition que lorsque R1 et R2 représentent hydrogène, R5 représente halogène ou alkyle inférieur.
PCT/JP2004/010235 2003-07-11 2004-07-09 Composé amino-alcool WO2005005383A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-273224 2003-07-11
JP2003273224 2003-07-11

Publications (1)

Publication Number Publication Date
WO2005005383A1 true WO2005005383A1 (fr) 2005-01-20

Family

ID=34056010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/010235 WO2005005383A1 (fr) 2003-07-11 2004-07-09 Composé amino-alcool

Country Status (2)

Country Link
TW (1) TW200510300A (fr)
WO (1) WO2005005383A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016133A1 (fr) 2006-08-04 2008-02-07 Daiichi Sankyo Company, Limited Enzyme de phosphorylation d'un médicament
EP2149549A4 (fr) * 2007-05-25 2012-01-04 Daiichi Sankyo Co Ltd Composition pharmaceutique destinée à la prévention ou au traitement de l'hépatite
WO2012073991A1 (fr) * 2010-12-02 2012-06-07 第一三共株式会社 Dérivé du pyrrole et procédé pour sa production

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006268A1 (fr) * 2000-07-13 2002-01-24 Sankyo Company, Limited Derives d'alcool amino
WO2003059880A1 (fr) * 2002-01-11 2003-07-24 Sankyo Company, Limited Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006268A1 (fr) * 2000-07-13 2002-01-24 Sankyo Company, Limited Derives d'alcool amino
WO2003059880A1 (fr) * 2002-01-11 2003-07-24 Sankyo Company, Limited Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016133A1 (fr) 2006-08-04 2008-02-07 Daiichi Sankyo Company, Limited Enzyme de phosphorylation d'un médicament
US8071300B2 (en) 2006-08-04 2011-12-06 Daiichi Sankyo Company, Limited Drug-phosphorylating enzyme
EP2149549A4 (fr) * 2007-05-25 2012-01-04 Daiichi Sankyo Co Ltd Composition pharmaceutique destinée à la prévention ou au traitement de l'hépatite
WO2012073991A1 (fr) * 2010-12-02 2012-06-07 第一三共株式会社 Dérivé du pyrrole et procédé pour sa production
US8846943B2 (en) 2010-12-02 2014-09-30 Daiichi Sankyo Company, Limited Pyrrole derivative and process for production thereof

Also Published As

Publication number Publication date
TW200510300A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
TWI355934B (en) Pharmaceutical composition for treatment or prophy
EP2393809B1 (fr) Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
EP1551803B1 (fr) Derives azabicyclo utilises comme antagonistes des recepteur muscariniques
EP2167083B1 (fr) 1- hétéroaryl-3-azabicyclo[3.1.0]hexanes, leurs méthodes de préparation et leur utilisation comme médicaments
WO2002006268A1 (fr) Derives d'alcool amino
CA2868321A1 (fr) Inhibiteurs de kynurenine-3-monooxygenase, compositions pharmaceutiques, et procedes d'utilisation de ceux-ci
WO2016031987A1 (fr) Dérivé de pyrimidone ayant une activité inhibitrice de l'autotaxine
EP1807421A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
KR20220101071A (ko) 새로운 화합물
CN107709301B (zh) 吡唑衍生物或其药理学上可接受的盐
EP4013751A1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
OA12359A (fr) Aminoalkybenzoyl-benzofuranes ou benzothiophènes, leur procédé de préparation et les compositions les contenant.
EP2059503B1 (fr) Dérivés d'aminopyrazole, leur procédé de préparation, et composition pour la prévention ou le traitement de maladies ischémiques contenant ces dérivés
WO2004063156A1 (fr) Nouveaux derives d'indole utiles comme inhibiteurs de fabp-4
JP2000508670A (ja) ピペリジン化合物およびピロリジン化合物
JP2005047899A (ja) アミノアルコール化合物
WO2003101983A1 (fr) Derive tetrahydropyrane
JP2006188452A (ja) アミノアルコール化合物を含有する医薬組成物
CA2629738C (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant
EP0381235B1 (fr) Dérivés de pyrrolidine et leur utilisation pharmaceutique
WO2005005383A1 (fr) Composé amino-alcool
EP0463944B1 (fr) Acyl benzoxazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JP7142406B2 (ja) インドリジン誘導体及びその医学的応用
WO2005063671A1 (fr) Derives d'ether
KR100453301B1 (ko) 1-트리플루오로메틸-4-히드록시-7-피페리디닐-아미노메틸크로만 유도체

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP